Cipla

Cipla EBIT

The EBIT of Cipla (CIPLA.NS) as of Oct 11, 2026 is 52.70 B INR. In the previous year, EBIT was 105.63 B INR — a change of -50.11% (lower).

EBIT

52.70 BINR

YoY

-50.11%

Last updated:

In 2026, Cipla's EBIT was 52.70 B INR, a -50.11% increase from the 105.63 B INR EBIT recorded in the previous year.

The Cipla EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2023
77.96 B INR
Jan 1, 2024
94.80 B INR
Jan 1, 2025
105.63 B INR
Jan 1, 2026
52.70 B INR
Jan 1, 2027 (e)
56.92 B INR
Jan 1, 2028 (e)
70.93 B INR
Jan 1, 2029 (e)
79.88 B INR
Jan 1, 2030 (e)
119.57 B INR
The Cipla EBIT history
YEAREBITYoY
est119.57 BINR+49.69%
est79.88 BINR+12.60%
est70.93 BINR+24.61%
est56.92 BINR+8.01%
52.70 BINR-50.11%
105.63 BINR+11.42%
94.80 BINR+21.60%
77.96 BINR-3.58%
80.85 BINR+9.96%
73.53 BINR+9.63%
67.07 BINR+6.59%
62.93 BINR+6.61%
59.03 BINR+6.72%
55.31 BINR+2.59%
53.91 BINR+17.44%
45.91 BINR0.00%
45.91 BINR+143.01%
18.89 BINR+56.39%
12.08 BINR-124.20%
-49.92 BINR-498.09%
12.54 BINR+34.87%
9.30 BINR+10.96%
8.38 BINR+3.79%
8.07 BINR—
Access this data via the Eulerpool API

Cipla Revenue

Cipla Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
225.59 B INR
77.96 B INR
28.02 B INR
Jan 1, 2024
255.37 B INR
94.80 B INR
41.22 B INR
Jan 1, 2025
272.67 B INR
105.63 B INR
52.73 B INR
Jan 1, 2026
281.63 B INR
52.70 B INR
38.79 B INR
Jan 1, 2027 (e)
309.34 B INR
56.92 B INR
41.26 B INR
Jan 1, 2028 (e)
347.09 B INR
70.93 B INR
52.11 B INR
Jan 1, 2029 (e)
379.29 B INR
79.88 B INR
57.94 B INR
Jan 1, 2030 (e)
431.70 B INR
119.57 B INR
87.04 B INR

Cipla Margins

Cipla stock margins

The Cipla margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cipla. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cipla.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
62.52 %
34.56 %
12.42 %
Jan 1, 2024
64.58 %
37.12 %
16.14 %
Jan 1, 2025
66.35 %
38.74 %
19.34 %
Jan 1, 2026
42.74 %
18.71 %
13.77 %
Jan 1, 2027 (e)
42.74 %
18.40 %
13.34 %
Jan 1, 2028 (e)
42.74 %
20.44 %
15.01 %
Jan 1, 2029 (e)
42.74 %
21.06 %
15.28 %
Jan 1, 2030 (e)
42.74 %
27.70 %
20.16 %

Cipla Stock analysis

What does Cipla do? Cipla Ltd is an Indian pharmaceutical company based in Mumbai. The company was founded in 1935 and is now one of the largest producers of generics worldwide. The name "Cipla" is an abbreviation for "Chemical, Industrial & Pharmaceutical Laboratories". Business Model: Cipla specializes in the production of high-quality generics. This means that they manufacture medication that has the same active ingredients as the original drugs. This allows them to offer medication at a significantly lower price. However, Cipla not only offers generics but also develops its own innovative medication. The focus is on therapy areas such as oncology, respiratory diseases, HIV/AIDS, diabetes, and cardiovascular diseases. Divisions: Cipla is divided into several divisions, including generics, specialty drugs, and biologics. The generics division is the company's core competence. Here, Cipla produces a variety of medications in different forms, such as tablets, capsules, suspensions, etc. The specialty drugs division focuses on innovative medications that are usually more expensive than generics. This includes medications for the treatment of cancer or autoimmune diseases. In the biologics division, Cipla produces biotechnology products based on the use of living cells. Products: Cipla offers a wide range of products, including medications for asthma, diabetes, hypertension, and infectious diseases. Some of the most well-known medications are Escitalopram (an antidepressant), Seroflo (an asthma medication), Tenofovir (an HIV medication), and Sorafenib (a cancer medication). The company continuously works on new products and invests heavily in research and development. Cipla also has a social responsibility. The company is involved in the fight against HIV/AIDS and produces life-saving medication for this disease at an affordable price. Furthermore, Cipla has launched a program called "Cipla Foundation" which works towards improving healthcare in developing countries. Overall, Cipla has achieved impressive growth and is now one of the most significant pharmaceutical companies worldwide. The company has proven that it is possible to offer high-quality medication at an affordable price and still be successful. Cipla is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Cipla's EBIT

Cipla's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Cipla's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Cipla's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Cipla’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Cipla stock

EBIT of Cipla is 52.70 B INR in 2026.

EBIT of Cipla changed from 105.63 B INR to 52.70 B INR, representing a -50.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Cipla since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Cipla historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Cipla

All Key Metrics — Cipla